28406758|t|Fasting triglycerides as a predictor of incident diabetes, insulin resistance and β-cell function in a Canadian First Nation
28406758|a|Diabetes prevalence is substantially higher among Canadian First Nations populations than the non-First Nation population. Fasting serum triglycerides have been found to be an important predictor of incident diabetes among non-indigenous populations. However, there is a great need to understand diabetes progression within specific ethnic groups, particularly First Nations populations. The purpose of this study was to test for an association between fasting serum triglycerides and incident diabetes, changes in insulin resistance and changes in β-cell function in a Manitoba First Nation cohort. Study data were from two diabetes screening studies in Sandy Bay First Nation in Manitoba, Canada, collected in 2002/2003 and 2011/2012. The cohort was composed of respondents to both screening studies (n=171). Fasting blood samples and anthropometric, health and demographic data were collected. A generalised linear model with Poisson distribution was used to test for an association between fasting triglycerides and incident diabetes. There were 35 incident cases of diabetes among 128 persons without diabetes at baseline. Participants who developed incident type 2 diabetes were significantly older and had significantly higher body mass index (BMI; p=0.012), total cholesterol (p=0.007), fasting triglycerides (p<0.001), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (p<0.001). Fasting triglyceride level was found to be a statistically significant positive predictor of incident diabetes independent of age, sex and waist circumference at baseline. Participants with triglycerides in the highest tertile (≥2.11 mmol/l) had a 4.0-times higher risk of developing incident diabetes compared to those in the lowest tertile (p=0.03). Notably, neither waist circumference nor BMI were significant predictors of incident diabetes independent of age, sex and triglycerides. Fasting triglycerides may be useful as a clinical predictor of insulin resistance and diabetes development among First Nations populations. Unlike other ethnic groups, BMI and waist circumference may be less important factors in diabetes development.
28406758	0	7	Fasting	T033	C0015663
28406758	8	21	triglycerides	T109,T123	C0041004
28406758	27	36	predictor	T078	C2698872
28406758	40	48	incident	T067	C1551358
28406758	49	57	diabetes	T047	C0011847
28406758	59	77	insulin resistance	T046	C0021655
28406758	82	97	β-cell function	T043	C0007613
28406758	103	124	Canadian First Nation	T033	C0238884
28406758	125	133	Diabetes	T047	C0011847
28406758	134	144	prevalence	T081	C0033105
28406758	148	168	substantially higher	T080	C0205250
28406758	175	209	Canadian First Nations populations	T033	C0238884
28406758	219	246	non-First Nation population	T098	C1257890
28406758	248	255	Fasting	T033	C0015663
28406758	256	261	serum	T031	C0229671
28406758	262	275	triglycerides	T109,T123	C0041004
28406758	301	310	important	T080	C3898777
28406758	311	320	predictor	T078	C2698872
28406758	324	332	incident	T067	C1551358
28406758	333	341	diabetes	T047	C0011847
28406758	348	374	non-indigenous populations	T098	C1257890
28406758	396	401	great	T081	C0549177
28406758	421	429	diabetes	T047	C0011847
28406758	430	441	progression	T046	C0242656
28406758	449	457	specific	T080	C0205369
28406758	458	471	ethnic groups	T098	C0015031
28406758	486	511	First Nations populations	T033	C0238884
28406758	517	524	purpose	T169	C1285529
28406758	533	538	study	T062	C0681814
28406758	546	550	test	T169	C0039593
28406758	558	569	association	T080	C0439849
28406758	578	585	fasting	T033	C0015663
28406758	586	591	serum	T031	C0229671
28406758	592	605	triglycerides	T109,T123	C0041004
28406758	610	618	incident	T067	C1551358
28406758	619	627	diabetes	T047	C0011847
28406758	629	636	changes	T169	C0392747
28406758	640	658	insulin resistance	T046	C0021655
28406758	663	670	changes	T169	C0392747
28406758	674	689	β-cell function	T043	C0007613
28406758	695	703	Manitoba	T083	C0024726
28406758	710	716	Nation	T092	C1555720
28406758	717	723	cohort	T098	C0599755
28406758	725	735	Study data	T062	C0681873
28406758	750	758	diabetes	T047	C0011847
28406758	759	776	screening studies	T062	C2348164
28406758	780	802	Sandy Bay First Nation	T098	C1257890
28406758	806	814	Manitoba	T083	C0024726
28406758	816	822	Canada	T083	C0006823
28406758	866	872	cohort	T098	C0599755
28406758	889	900	respondents	T098	C0282122
28406758	904	908	both	T080	C1706086
28406758	909	926	screening studies	T062	C2348164
28406758	936	943	Fasting	T033	C0015663
28406758	944	957	blood samples	T031	C0178913
28406758	962	976	anthropometric	T081	C0815129
28406758	978	1005	health and demographic data	T078	C1511726
28406758	1011	1020	collected	T078	C1516695
28406758	1024	1035	generalised	T082	C0205246
28406758	1036	1048	linear model	T081	C0023732
28406758	1054	1074	Poisson distribution	T081	C0032347
28406758	1087	1091	test	T169	C0039593
28406758	1099	1110	association	T080	C0439849
28406758	1119	1126	fasting	T033	C0015663
28406758	1127	1140	triglycerides	T109,T123	C0041004
28406758	1145	1153	incident	T067	C1551358
28406758	1154	1162	diabetes	T047	C0011847
28406758	1178	1186	incident	T067	C1551358
28406758	1187	1192	cases	T169	C0868928
28406758	1196	1204	diabetes	T047	C0011847
28406758	1215	1222	persons	T098	C0027361
28406758	1231	1239	diabetes	T047	C0011847
28406758	1243	1251	baseline	T081	C1442488
28406758	1253	1265	Participants	T098	C0679646
28406758	1280	1288	incident	T067	C1551358
28406758	1289	1304	type 2 diabetes	T033	C3280267
28406758	1310	1329	significantly older	T098	C1518563
28406758	1338	1358	significantly higher	T081	C4055637
28406758	1359	1374	body mass index	T201	C1305855
28406758	1376	1379	BMI	T201	C1305855
28406758	1391	1396	total	T080	C0439810
28406758	1397	1408	cholesterol	T109,T123	C0008377
28406758	1420	1427	fasting	T033	C0015663
28406758	1428	1441	triglycerides	T109,T123	C0041004
28406758	1457	1507	Homeostatic Model Assessment of Insulin Resistance	T059	C3639411
28406758	1509	1516	HOMA-IR	T059	C3639411
28406758	1529	1536	Fasting	T033	C0015663
28406758	1537	1549	triglyceride	T109,T123	C0041004
28406758	1550	1555	level	T080	C0441889
28406758	1574	1599	statistically significant	T081	C0237881
28406758	1600	1608	positive	T033	C1446409
28406758	1609	1618	predictor	T078	C2698872
28406758	1622	1630	incident	T067	C1551358
28406758	1631	1639	diabetes	T047	C0011847
28406758	1640	1654	independent of	T169	C0332291
28406758	1655	1658	age	T032	C0001779
28406758	1660	1663	sex	T032	C1522384
28406758	1668	1687	waist circumference	T201	C0455829
28406758	1691	1699	baseline	T081	C1442488
28406758	1701	1713	Participants	T098	C0679646
28406758	1719	1732	triglycerides	T109,T123	C0041004
28406758	1740	1755	highest tertile	T080	C0205556
28406758	1787	1798	higher risk	T033	C3843761
28406758	1813	1821	incident	T067	C1551358
28406758	1822	1830	diabetes	T047	C0011847
28406758	1831	1839	compared	T052	C1707455
28406758	1856	1870	lowest tertile	T080	C0205556
28406758	1890	1897	neither	T080	C4284892
28406758	1898	1917	waist circumference	T201	C0455829
28406758	1922	1925	BMI	T201	C1305855
28406758	1931	1942	significant	T078	C0750502
28406758	1943	1953	predictors	T078	C2698872
28406758	1957	1965	incident	T067	C1551358
28406758	1966	1974	diabetes	T047	C0011847
28406758	1975	1989	independent of	T169	C0332291
28406758	1990	1993	age	T032	C0001779
28406758	1995	1998	sex	T032	C1522384
28406758	2003	2016	triglycerides	T109,T123	C0041004
28406758	2018	2025	Fasting	T033	C0015663
28406758	2026	2039	triglycerides	T109,T123	C0041004
28406758	2047	2053	useful	T080	C3827682
28406758	2059	2067	clinical	T080	C0205210
28406758	2068	2077	predictor	T078	C2698872
28406758	2081	2099	insulin resistance	T046	C0021655
28406758	2104	2112	diabetes	T047	C0011847
28406758	2113	2124	development	T169	C1527148
28406758	2131	2156	First Nations populations	T033	C0238884
28406758	2171	2184	ethnic groups	T098	C0015031
28406758	2186	2189	BMI	T201	C1305855
28406758	2194	2213	waist circumference	T201	C0455829
28406758	2221	2235	less important	T080	C3898777
28406758	2236	2243	factors	T169	C1521761
28406758	2247	2255	diabetes	T047	C0011847
28406758	2256	2267	development	T169	C1527148